{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Tango Therapeutics, Inc.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of October 31, 2025, Tango Therapeutics, Inc. has a bullish technical trend, supported by daily moving averages and a mildly bullish monthly MACD, despite a mildly bearish weekly MACD.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of October 31, 2025, the technical trend is bullish, supported by strong indicators like a bullish MACD and moving averages, although a mildly bearish KST slightly tempers the sentiment.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of October 31, 2025, Tango Therapeutics, Inc. has a bullish technical trend, supported by positive MACD and moving averages, with a year-to-date return of 162.46%, significantly outperforming the S&P 500's 16.30%.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of October 24, 2025, Tango Therapeutics, Inc. shows a mildly bullish trend overall, with mixed signals from various indicators including MACD, Bollinger Bands, and KST.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of October 24, 2025, Tango Therapeutics, Inc. shows a mildly bullish technical trend with mixed signals from indicators like MACD and KST, suggesting caution despite some short-term strength.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of October 24, 2025, Tango Therapeutics, Inc. shows a mildly bullish technical trend, supported by mixed signals from MACD, Bollinger Bands, and moving averages, despite underperforming over longer periods compared to the S&P 500.
Tango Therapeutics Hits Day High with 9.43% Surge in Stock Price
Tango Therapeutics, Inc. has seen a notable rise in its stock price, with a significant increase over the past week and month. However, the company faces financial challenges, including a decline in net profit and negative operating cash flow, complicating its overall market position.
Tango Therapeutics Hits New 52-Week High of $9.55, Marking Major Milestone
Tango Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant performance improvement over the past year. With a market capitalization of USD 758 million, the company faces challenges, including negative return on equity and a lack of dividend yield, while navigating a competitive biotechnology landscape.
Tango Therapeutics Hits New 52-Week High of $9.11, Showcasing Strong Growth
Tango Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant performance improvement over the past year. With a market capitalization of USD 758 million, the company faces challenges in financial metrics, including a negative return on equity and a high price-to-book ratio, amidst a competitive biotechnology landscape.
Tango Therapeutics Hits Day High with 18.63% Surge in Stock Price
Tango Therapeutics, Inc. has seen a notable rise in its stock price, achieving significant gains over the past week and month, as well as a remarkable year-to-date performance. However, the company faces challenges, including a decline in net profit and negative financial metrics, indicating a risky position in the competitive biotechnology sector.
Tango Therapeutics Hits New 52-Week High of $8.79, Marking Major Milestone
Tango Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant year-over-year performance. With a market capitalization of USD 758 million, the company operates in a competitive biotechnology sector, facing challenges such as negative return on equity and a high price-to-book ratio, indicating premium valuation.
Tango Therapeutics Hits New 52-Week High at $8.56
Tango Therapeutics, Inc. has achieved a new 52-week high of USD 8.56, significantly up from its low of USD 1.03, reflecting a year-over-year performance of 19.13%. With a market cap of USD 758 million, the company faces challenges, including a negative return on equity and no dividend yield.
Tango Therapeutics Hits New 52-Week High of $8.19, Marking Major Milestone
Tango Therapeutics, Inc. has achieved a new 52-week high of USD 8.19, significantly up from its low of USD 1.03. Despite this milestone, the company's one-year performance lags behind the S&P 500. With a market cap of USD 758 million, it remains a loss-making micro-cap stock.
Tango Therapeutics Hits Day High with Strong 7.14% Intraday Surge
Tango Therapeutics, Inc. has experienced notable stock performance, with significant gains over the past week and month, as well as year-to-date. However, the company faces challenges, including a recent decline in net profit and negative operating cash flow, highlighting financial strain despite its market presence.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of September 2, 2025, Tango Therapeutics, Inc. has a mildly bullish technical trend, supported by bullish MACD and Bollinger Bands, despite mixed signals from KST and a year-to-date performance of 154.69% compared to the S&P 500's 12.22%.
Is Tango Therapeutics, Inc. overvalued or undervalued?
As of August 9, 2021, Tango Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a high Price to Book Value of 2.77, an EV to Sales ratio of 6.04, a troubling ROE of -79.32%, and a less efficient EV to EBITDA ratio compared to peers, despite a strong year-to-date stock return of 154.69%.
Is Tango Therapeutics, Inc. overvalued or undervalued?
Tango Therapeutics, Inc. is considered risky and overvalued due to its negative P/E ratio of -3.94, troubling financial metrics, and a significant -79.32% Return on Equity, despite a recent strong performance against the S&P 500.
Is Tango Therapeutics, Inc. technically bullish or bearish?
As of May 15, 2025, the trend is mildly bearish due to daily moving averages and monthly MACD indicating bearish sentiment, despite some short-term strength from weekly indicators, suggesting caution amid mixed signals.
What does Tango Therapeutics, Inc. do?
Tango Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $5 million and a net loss of $40 million. It has a market cap of $520.83 million and key metrics indicating significant financial challenges.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
